Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 2/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.47 |
| ▸ | LIPE | Q05469 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4576825 | 0.87 | EPHX2 (0.56) | EPHX2KMT2AKCNH2MCHR1MEN1 | |
| SCHEMBL4577583 | 0.86 | EPHX2 (0.52) | EPHX2KMT2ALIPEMEN1POLB | |
| SCHEMBL4578078 | 0.85 | YAP1 (0.55) | EPHX2KMT2ALIPEMEN1 | |
| SCHEMBL17422616 | 0.85 | EPHX2 (0.56) | EPHX2KMT2AKCNH2LIPE | |
| Hydrochloric Acid SCHEMBL27826424 | 0.84 | MLNR (0.52) | MLNRADRB2EPHX2KMT2AKCNH2 | |
| SCHEMBL27900122 | 0.82 | ADRB2 (0.53) | MLNRADRB2EPHX2KCNH2MCHR1 | |
| SCHEMBL6443342 | 0.82 | POLB (0.60) | MLNREPHX2KMT2AMEN1POLB | |
| SCHEMBL2773240 | 0.81 | EPHX2 (0.53) | MLNRADRB2EPHX2KMT2APLA2G1B | |
| SCHEMBL4578888 | 0.81 | ADRB2 (0.52) | MLNRADRB2EPHX2KCNH2MCHR1 | |
| SCHEMBL20857043 | 0.81 | YAP1 (0.50) | EPHX2KMT2ALIPEPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534677-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1ALPHA BINDING TO ITS RECEPTOR CCR1 | Pfizer Products Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040063759-A1 | Novel piperidine derivatives | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2004009550-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1ALPHA BINDING TO ITS RECEPTOR CCR1 | PFIZER PRODUCTS INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063759-A1 | Novel piperidine derivatives | CCR1, CCR3, CCR2 | MLNR 760/4885ADRB2 686/4885EPHX2 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.